ClinicalTrials.gg
CompletedNCT04238364Updated Jun 9, 2026

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

A Phase 1 interventional study of EI-1071 and Placebo in Healthy Volunteers, sponsored by Elixiron Immunotherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Elixiron Immunotherapeutics Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.

Read the detailed description

This phase 1 first-in-human study was designed to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of EI1071 when administered to healthy adult volunteers. This was a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort trial. The study was conducted in two phases: a single ascending dose (SAD) phase, followed by a multiple ascending dose (MAD) phase. Approximately 58 healthy volunteers enrolled in SAD and MAD cohorts (34 in SAD; 24 in MAD). In SAD, participants in Cohorts 1 to 5 received one dose of EI-1071 or placebo. In MAD, participants in Cohorts 1 and 2 received multiple doses of EI-1071 or placebo for 14 consecutive days. Safety, tolerability, and PK profile of EI-1071 were assessed.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • CSF1R Inhibitor
  • Safety
  • Tolerability
  • Pharmacokinetics
  • EI1071
03

In context

Lead sponsor

Elixiron Immunotherapeutics Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects were eligible for enrollment in the study only if they met all the following criteria:

  1. Healthy male and female subjects, 18 to 45 years of age, inclusive. (Taiwan only: To be at least 20 years of age.)
  2. The subject had a (BMI) of 18.0 to 30.0 kg/m2, inclusive, and weighs at least 50kg.
  3. The subject was in good health and has no medical condition of clinical significance or that may impact the outcome of the study, as determined by the investigator (as determined by medical history, physical examination, 12-lead [ECG], vital signs, and clinical laboratory results at screening).
  4. The subject was able to understand the nature of the study and any potential hazards associated with participating in it.
  5. The subject was able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study.
  6. The subject was willing to provide written to participate in the study after reading the informed consent form and the information provided, and has had the opportunity to discuss the study with the investigator or designee.
  7. Negative pregnancy test for female subjects. Women of child bearing potential and Women not of child bearing potential were eligible to participate. Both women of child bearing potential and women of no child bearing potential used an approved method of and agrees to continue to use this method for the duration of the study (and for 90 days after taking the last dose of EI1071). Acceptable methods of contraception included abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method, female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner was surgically sterile or 2 years . All male subjects/partners must agree to consistently and correctly use a condom. In addition, subjects may not donate sperm for the duration of the study and for 90 days after taking study drug.
  8. Subject was currently not using strong inhibitors or inducers of and was not anticipated to use these for the duration of the study

Exclusion criteria

Exclusion Criteria:

Subjects were eligible for enrollment in the study only if they meet none of the following criteria:

  1. The subject had a history of severe allergic or anaphylactic reactions.
  2. The subject had a known allergy or to any component of the formulation.
  3. The subject had a medical history or current evidence of any (as determined by the investigator) cardiac, endocrine (including diabetes), hematologic, hepatobiliary (abnormal [ALT], aspartate aminotransferase [AST], gamma-glutamyl transpeptidase [GGT], or total ), immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal condition, or other major disease.
  4. The subject had a history of any malignant disease.
  5. The subject had a history of more than one herpes zoster episode or multidermatomal herpes zoster.
  6. The subject had a history of an opportunistic infection (e.g. cytomegalovirus, pneumocystis carinii, aspergillosis, clostridium difficile).
  7. The subject had a history of or ongoing chronic or recurrent infectious disease (e.g. infected indwelling prosthesis, osteomyelitis, chronic sinusitis).
  8. The subject had major trauma or surgery in the 2 months before screening or at any time between screening and check-in.
  9. The subject had an acute infection within 2 weeks before screening or at any time between screening and check-in including, but not limited to, history, signs, or symptoms of a common cold (eg, mild rhinorrhea), untreated oral/dental abnormalities (e.g. untreated dental caries as determined by examination of the mouth), or untreated disruption of the skin.
  10. The subject had clinically significant abnormal findings at screening, check-in visits, or predose, as determined by the Investigator.
  11. The subject had a supine blood pressure measurement outside the ranges of 90 to 140 mm Hg systolic or 45 to 90 mm Hg diastolic (measured after a rest of at least 5 minutes) at screening, check-in, or predose. Note: If either value was out of the range, blood pressure measurements may be repeated in the supine position at intervals of 5 to 10 minutes up to 3 times. If the mean systolic or diastolic measurement continues to exceed the stated limits, the subject will be excluded.
  12. The subject had a pulse of fewer than 45 beats per minute (bpm) or greater than 100 bpm(measured after a rest of at least 5 minutes) at screening, check-in, or predose.
  13. The subject tests positive for tuberculosis (TB) at screening by the QuantiFERON-TB Gold Test, or has a history of latent, inadequately treated, or active TB.
  14. The subject had a known history of, or a positive test result for, surface antigen (HBsAg), virus (HCV), or (HIV) types 1 or 2 at screening.
  15. The subject had used prescription or over-the-counter (OTC) medication (other than ≤2 g/day paracetamol [acetaminophen] or ≤800 mg/day ibuprofen), vitamins, or herbal remedies, within 2 weeks or 5 half-lives before study drug administration, whichever was longer.
  16. The subject had participated in another clinical study of a new drug or has received an investigational drug within the 3 months or 5 half-lives (if available) before study drug administration, whichever is longer.
  17. The subject had a loss of more than 400 mL of blood (e.g. a blood donation) within 2 months before study drug administration, or has received any blood, plasma, or transfusions within 3 months before check-in, or plans to donate blood during the study or within 3 months after the study.
  18. The subject had a history of alcohol abuse (defined as an alcohol intake more than 21 units per week) or a history of drug abuse within the 6 months before study drug administration, or a history of substance abuse deemed significant by the investigator. A unit of alcohol is defined as 240 mL of beer, 120 mL of wine, or 1 single shot of spirits. The subject will be required to abstain from alcohol consumption 48 hours prior to screening or check-in.
  19. The subject was a current smoker or has a history of smoking.
  20. The subject had a positive test for alcohol or drugs of abuse (barbiturates, methamphetamine, benzodiazepines, morphine/opiates, phencyclidine (PCP), amphetamines, tetrahydrocannabinol (THC), methylenedioxymethamphetamine (MDMA), cocaine, methadone, and cotinine) at screening or check-in.
  21. The subject was unable to participate in, or successfully complete, the study, in the opinion of their general practitioner or the investigator, because the subject was any of the following:

    1. mentally or legally incapacitated, or unable to give consent for any reason
    2. in custody due to an administrative or a legal decision, or under tutelage, or being admitted to a sanitarium or social institution
    3. unable to be contacted in case of emergency
    4. unlikely to cooperate or comply with the clinical study protocol or was unsuitable for any other reason
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    EI-1071 Tablet

    EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)

    Drug: EI-1071

  • Placebo comparator
    Placebo

    EI-1071 tablet(s) administered orally as single ascending dose(SAD), multiple ascending daily dose(MAD)

    Drug: Placebo

Interventions

  • EI-1071 Tablet(s)

  • DrugPlacebo

    Matching Placebo Tablet(s)

06

What researchers measure

Primary outcomes

  1. After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) after dosing with EI-1071

    Experience at least 1 treatment-emergent adverse event

    Time frame: Up to 7 days

  2. After multiple ascending doses, number of subjects with TEAEs after dosing with EI-1071

    Experienced at least 1 treatment-emergent adverse event

    Time frame: Up to 21 days

  3. After multiple ascending doses, number of subjects with adverse events (AEs) leading to discontinuation in the EI-1071 cohorts.

    Discontinued due to adverse event

    Time frame: Up to 14 days

Secondary outcomes

  1. Cmax

    Maximum observed serum concentration

    Time frame: Single dose: up to 48 hours; Multiple dose: up to 16 days

  2. Tmax

    Time to reach Cmax

    Time frame: Single dose: up to 48 hours; Multiple dose: up to 16 days

  3. t1/2

    Terminal half-life

    Time frame: Single dose: up to 48 hours; Multiple dose: up to 16 days

  4. AUC-last

    Area under the curve from the time of dosing to the time of the last measurable concentration

    Time frame: Single dose: up to 48 hours; Multiple dose: up to 16 days

  5. AUC-inf

    Area under the curve from the time of dosing extrapolated to infinity

    Time frame: Single dose: up to 48 hours; Multiple dose: up to 16 days

  6. Colony Stimulating Factor 1 (CSF1) concentration in blood after multiple-dose administration

    Amount of Colony Stimulating Factor 1

    Time frame: Up to 15 days

  7. Monocyte count in blood after multiple-dose administration

    Count of monocyte subsets

    Time frame: Up to 15 days

07

Study locations

1 site
  • Parexel Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Dec 2021, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 23, 2020
StartActual
Dec 27, 2019
Primary completionActual
Dec 16, 2021
CompletionActual
Jan 10, 2022
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04238364
Lead sponsor
Elixiron Immunotherapeutics Inc.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Dec 27, 2019
Primary completion
Dec 16, 2021
Completion
Jan 10, 2022
Last update
Jun 9, 2026

Study contacts

Chi-Yun Pai
study director · Elixiron Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enrupatinib

Start the discussion